Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANTOS vascular MRI substudy: canakinumab for prevention of recurrent cardiovascular events and reduction of carotid plaque burden
2012-003010-14Phase 3Terminated
- Sponsor
- Novartis
- Start
- Oct 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of canakinumab in atherosclerosis, myocardial infarction (MI), cardiac morbidity, sponsored by Novartis. Started Oct 2012; status: terminated.
02
Drugs
canakinumab
03
Conditions
atherosclerosismyocardial infarction (MI)cardiac morbidity
Beyond the preview
Go deeper on 2012-003010-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003010-14.